Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Payables (2019 - 2025)

Historic Payables for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $2.3 million.

  • Keros Therapeutics' Payables fell 5386.47% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 5386.47%. This contributed to the annual value of $4.6 million for FY2024, which is 1555.96% down from last year.
  • Keros Therapeutics' Payables amounted to $2.3 million in Q3 2025, which was down 5386.47% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' Payables peaked at $7.7 million during Q2 2022, and registered a low of $1.4 million during Q2 2021.
  • Moreover, its 5-year median value for Payables was $4.1 million (2023), whereas its average is $4.3 million.
  • In the last 5 years, Keros Therapeutics' Payables tumbled by 7172.3% in 2021 and then skyrocketed by 45830.9% in 2022.
  • Over the past 5 years, Keros Therapeutics' Payables (Quarter) stood at $3.6 million in 2021, then dropped by 8.4% to $3.3 million in 2022, then soared by 63.22% to $5.4 million in 2023, then dropped by 15.56% to $4.6 million in 2024, then tumbled by 50.07% to $2.3 million in 2025.
  • Its Payables was $2.3 million in Q3 2025, compared to $5.3 million in Q2 2025 and $6.6 million in Q1 2025.